NexPlasmaGen to present at the MedInvest Oncology Investor Conference | NexPlasmaGen
post-template-default,single,single-post,postid-17075,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.0,vc_responsive

NexPlasmaGen to present at the MedInvest Oncology Investor Conference

NexPlasmaGen to present at the MedInvest Oncology Investor Conference

Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference.

The MedInvest Oncology Investor Conference will be hosted in person June 28-29, 2022 in New York City at the  One Vanderbilt Avenue. NexPlasmaGen was selected to present on June 28 at 14h50 EST. Over 30 cancer startups, early pre-clinical through clinical, public and private, are expected to present, and over 100+ investors spanning venture, public funds, foundations, family offices, angels, and government grant making entities are expected to attend.

“It is a real privilege to present NexPlasmaGen at this conference so we can meet investors and strategic partners to close our Seed round and discuss future partnerships!”, indicated Dr Valérie Léveillé, CEO of NexPlasmaGen.


The event is the preeminent indication specific investor conference. The attendees are active investors in the oncology space and oncology-focused companies seeking investment.  The meetings of the Oncology Investor Conference have been held twice a year since 2017. The National Cancer Institute and McDermott Will & Emery Law Firm are the Presenting Partners.

For more information about the upcoming conference visit


NexPlasmaGen is striving to converge the emerging field of cold plasma biotechnology for personalized cancer care. We are developing high precision cold plasma delivery systems with the potential to selectively kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen first application is in breast cancer care, applying its patented cold plasma device to improve patient outcomes in breast conserving therapy.

For more information about NexPlasmaGen, contacts: Valérie Léveillé, CEO/Founder, 1-514-229-9458, and visit our web site at NexPlasmaGen.


NexPlasmaGen, MedInvest Oncology Investor Conference, Clinical trials




No Comments

Post A Comment